Corcept officer exercises 75K options, sells 75K shares
Corcept Therapeutics officer Sean Maduck reported an option exercise and related share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Corcept Therapeutics officer Sean Maduck reported an option exercise and related share sales. He exercised stock options for 75,000 shares of common stock at a $8.27 exercise price, then sold 20,425 shares at $66.1599 and 54,575 shares at $65.3711 in open-market transactions.
The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. After the transactions, he held 29,402 shares directly, plus additional indirect holdings through trusts and LLCs associated with him, which include restricted stock awards that vest over time.
Insider Trade Summary 10b5-1
Exercise and Sale: 75,000 shares ($4.30M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Maduck Sean
Role
See Remarks
Sold
75,000 shs ($4.92M)
Approx. gross sale proceeds
$4.92M
Approx. exercise cost
$620K
Approx. pre-tax spread
$4.30M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 75,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 75,000 | $8.27 | $620K |
| Sale | Common Stock | 54,575 | $65.3711 | $3.57M |
| Sale | Common Stock | 20,425 | $66.1599 | $1.35M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 166,986 contracts (Direct);
Common Stock — 8,977 shares (Direct);
Common Stock — 109,717 shares (Indirect, See Footnote)
Footnotes (10)
- F1. Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
- F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $65.00 to $65.99 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $66.00 to $66.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F5. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
- F6. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
- F7. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F8. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F9. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- F10. Fully exercisable.
Key Figures
Shares sold at $66.1599: 20,425 shares
Shares sold at $65.3711: 54,575 shares
Options exercised: 75,000 shares at $8.27
+5 more
8 metrics
Shares sold at $66.1599
20,425 shares
Open-market sale at weighted average price on May 27, 2026
Shares sold at $65.3711
54,575 shares
Open-market sale at weighted average price on May 27, 2026
Options exercised
75,000 shares at $8.27
Stock option (right to buy) exercise on May 27, 2026
Direct holdings after trades
29,402 shares
Common stock directly held following May 27, 2026 transactions
Indirect living trust holdings
10,000 shares
Sean and Molly Maduck Living Trust indirect ownership entry
MMM 2025, LLC holdings
34,000 shares
Indirect ownership through MMM 2025, LLC
Duckhill Capital, LLC holdings
5,147 shares
Indirect holdings with pecuniary interest disclaimer
Option expiration
February 10, 2027
Expiration date of exercised stock option grant
Key Terms
Rule 10b5-1 plan, Grantor Retained Annuity Trust, restricted stock awards, weighted average sale price, +2 more
6 terms
Rule 10b5-1 plan financial
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Grantor Retained Annuity Trust financial
"Represents the shares held by SNM 2025 Grantor Retained Annuity Trust"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
restricted stock awards financial
"Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold."
pecuniary interest financial
"disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."
stock option (right to buy) financial
"security_title: Stock option (right to buy)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Corcept Therapeutics (CORT) report for Sean Maduck?
Sean Maduck exercised options for 75,000 shares and sold 75,000 shares of Corcept common stock. The sales were executed in two open-market transactions on May 27, 2026, following the option exercise, and were conducted under a pre-arranged Rule 10b5-1 trading plan.
What stock options did Sean Maduck exercise at Corcept Therapeutics (CORT)?
Maduck exercised stock options covering 75,000 Corcept common shares at an $8.27 exercise price. The options were fully exercisable and were tied to a derivative position labeled as a stock option (right to buy) that was scheduled to expire on February 10, 2027.
What indirect Corcept Therapeutics (CORT) holdings are associated with Sean Maduck?
Indirect holdings include shares in a living trust, LLCs, and grantor retained annuity trusts. The entities include the Sean and Molly Maduck Living Trust, MMM 2025, LLC, SNM 2025 and 2026 Grantor Retained Annuity Trusts, and Duckhill Capital, LLC, with certain economic interests and disclaimers noted.
AI-generated analysis. How Rhea-AI works. Not financial advice.
